Donor-derived cell-free DNA in lung transplant patients with chronic dysfunction
Author Information
Author(s): Beeckmans H., Pagliazzi A., Kerckhof P., Hofkens R., Debackere F., Zajacova A., Bos S., Vanaudenaerde B. M., de Loor H., Naesens M., Vos R.
Primary Institution: KU Leuven, Leuven, Belgium
Hypothesis
Can donor-derived cell-free DNA levels serve as a biomarker for monitoring lung allograft health in chronic lung allograft dysfunction (CLAD) patients?
Conclusion
The study found that elevated levels of donor-derived cell-free DNA indicate ongoing allograft injury in lung transplant patients with chronic lung allograft dysfunction.
Supporting Evidence
- 47% of stable samples showed elevated dd-cfDNA levels.
- 66% of preclinical CLAD samples had elevated dd-cfDNA levels.
- 71% of established CLAD samples exhibited elevated dd-cfDNA levels.
- High variability in dd-cfDNA levels was observed among patients.
- dd-cfDNA levels did not significantly differ between BOS and RAS.
Takeaway
Researchers looked at blood samples from lung transplant patients to see if a specific DNA marker could help detect problems with their lungs. They found that many patients had high levels of this marker, which suggests their lungs were injured.
Methodology
The study measured donor-derived cell-free DNA levels in blood samples from lung transplant patients at different stages of chronic lung allograft dysfunction.
Potential Biases
Potential selection bias due to exclusion criteria.
Limitations
The study was limited by its single-center design, small sample size, and exclusion of samples during concurrent acute rejection or infection.
Participant Demographics
{"age":{"median":56,"range":"49-63"},"sex":{"female":10,"percentage":50},"native_lung_disease":{"COPD":15,"ILD":1,"CF":1,"CLAD":2,"BRECT":1}}
Statistical Information
P-Value
0.25
Statistical Significance
p=0.25
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website